EGFR and non-small cell lung carcinoma: This is most likely due to not only the inclusion of both treatment-naive and previously treated patients in the analysis but also a bias created by liquid biopsy ordering patterns (eg, clinicians order liquid biopsies at disease progression for patients with EGFR-mutant NSCLC more frequently than for patients undergoing nontargeted therapies).